Voriconazole therapeutic drug monitoring: focus on safety

被引：66

作者：

Pasqualotto, Alessandro C. ^{[1
,2
]}

Xavier, Melissa O. ^{[3
]}

Andreolla, Huander F. ^{[4
]}

Linden, Rafael ^{[5
]}

机构：

[1] Hosp Dom Vicente Scherer, Mol Diagnost Lab, BR-90035075 Porto Alegre, RS, Brazil

[2] Univ Fed Rio Grande do Sul, Post Grad Program Pulm Sci, Porto Alegre, RS, Brazil

[3] Univ Fed Rio Grande, Mycol Lab, Rio Grande, Brazil

[4] Univ Fed Rio Grande do Sul, Post Grad Program Gastroenterol Sci, Porto Alegre, RS, Brazil

[5] Ctr Univ Feevale, Sch Pharm, Novo Hamburgo, Brazil

来源：

EXPERT OPINION ON DRUG SAFETY | 2010年 / 9卷 / 01期

关键词：

adverse effects; CYP2C19; protein; drug monitoring; drug toxicity; voriconazole; PERFORMANCE LIQUID-CHROMATOGRAPHY; ANTIFUNGAL THERAPY; AMPHOTERICIN-B; HUMAN PLASMA; PHARMACOKINETICS; EFFICACY; HEALTHY; ASSAY; QUANTIFICATION; ASPERGILLOSIS;

D O I：

10.1517/14740330903485637

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Importance of the field: Voriconazole has been widely used for the treatment of invasive fungal diseases, particularly invasive aspergillosis. Drug drug interactions are, however, the main drawback associated with voriconazole use, since this drug suffers from extensive hepatic metabolism. Areas covered in this review: This article reviews the current literature on voriconazole therapeutic drug monitoring, with a special focus on drug safety. What the reader will gain: An update on voriconazole metabolism, drug interactions, toxicity and the relation of these with voriconazole drug concentrations. Take home message: Therapy with voriconazole may be better guided by measuring voriconazole concentrations in the plasma.

引用

页码：125 / 137

页数：13

共 66 条

[11]

Das S, 2009, INDIAN PEDIATR, V46, P225

[12] Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats [J].

de Araujo, Bibiana Verlindo ;

da Silva, Cristofer Farias ;

Haas, Sandra Elisa ;

Dalla Costa, Teresa .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (02) :154-159

[13] Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections [J].

den Hollander, Jan G. ;

van Arkel, Cornelis ;

Rijnders, Bart J. ;

Lugtenburg, Pieternella J. ;

de Marie, Siem ;

Levin, Mark-David .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (06) :1248-1250

[14] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].

Denning, DW ;

Ribaud, P ;

Milpied, N ;

Caillot, D ;

Herbrecht, R ;

Thiel, E ;

Haas, A ;

Ruhnke, M ;

Lode, H .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571

[15] Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole [J].

Denning, DW ;

Griffiths, CEM .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (08) :648-653

[16] Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman [J].

Elter, Thomas ;

Sieniawski, Michal ;

Gossmann, Axel ;

Wickenhauser, Claudia ;

Schroeder, Ursula ;

Seifert, Harald ;

Kuchta, Johannes ;

Burhenne, Juergen ;

Riedel, Klaus-Dieter ;

Faetkenheuer, Gerd ;

Cornely, Oliver A. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 28 (03) :262-265

[17]

*FDA, 2001, 0212662008 FDA NDA

[18] A rapid HPLC assay for voriconazole in human plasma [J].

Gage, R ;

Stopher, DA .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (08) :1449-1453

[19] Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection [J].

Gordien, Jean-Baptiste ;

Pigneux, Arnaud ;

Vigouroux, Stephane ;

Tabrizi, Reza ;

Accoceberry, Isabelle ;

Bernadou, Jean-Marc ;

Rouault, Audrey ;

Saux, Marie-Claude ;

Breilh, Dominique .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2009, 50 (05) :932-938

[20]

HEIZ WJ, 2009, 49 INT C ANT AG CHEM

← 1 2 3 4 5 6 7 →